Mohr Sector Navigator ETF ENAV 深 滬
等待開盤 10-24 09:30:00 美东时间
24.117
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 24.117
- 總市值 1748.48万
- 52周最高 25.0923
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 22.4723
- 委 比 0.00%
- 總股本 72.50万
- 歷史最高 25.0923
- 量 比 0
- 振 幅 0.00%
- 歷史最低 22.4723
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ClearBridge Global Infrastructure Fund adds ENAV, Iberdrola; Exits Eletrobras, Pembina, EDP
ClearBridge Global Infrastructure Income Strategy underperformed the FTSE Global Core Infrastructure 50/50 in the third quarter, driven primarily by stock selection in the electric utility, water util...
10-14 01:10
Outlook Therapeutics Requests FDA Meeting To Clarify Confirmatory Evidence Requirements For ONS-5010 Wet AMD Biologics License Application
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has
09-02 20:36
Ena S.p.A. Completes Reserved Capital Increase, Alters Shareholding Structure
An update from Enav SpA ( ($IT:ENAV) ) is now available. Ena S.p.A. announced t...
06-28 00:55
Ena S.p.A. Announces New Director Nominations
Enav SpA ( ($IT:ENAV) ) has provided an announcement. Ena S.p.A. announced that...
06-26 01:03
Outlook Therapeutics Secures SMC Approval For LYTENAVA As First And Only Licensed Ophthalmic Bevacizumab For Wet AMD Treatment In UK, Has An Initial 10 Years Of Market Exclusivity From The Date Of Initial Marketing Authorization From The Medicines And Healthcare Products Regulatory Agency
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium
06-10 20:10
Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab
06-02 19:09
Enav S.p.A. Announces Shareholders’ Meeting for 2025
Enav SpA ( ($IT:ENAV) ) has issued an update. Enav S.p.A. has announced the con...
04-18 18:12
Which European equities to buy as UBS upgrades to Overweight?
UBS strategists compiled a list of their high conviction buys within European stocks (VGK), (IEV), (IEUR), (STOXX), (FEZ). In a Thursday note, Andrew Garthwaite, chief global equity strategist at UBS,...
02-14 01:26
Ena S.p.A. Sells Energetika to Refocus on Core Business
Enav SpA ( ($IT:ENAV) ) has shared an announcement. Ena S.p.A. has sold its who...
02-13 04:02
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.
01-17 01:09
